AI technology company Ultromics secures $55 million inSeries C funding for expanding its AI-powered heart failure detection solutions.
Ultromics' AI-Powered Cardiology Diagnostics Making Waves
Ultromics, an Oxford-based company, has made significant strides in the field of cardiology with its AI-driven diagnostics platform. The platform, which uses AI to uncover hidden disease signals within standard echocardiograms, is making earlier and more accurate detection of complex heart conditions possible [1].
In a move that marks a major advancement, Ultromics' EchoGo® received FDA Breakthrough Device clearance for EchoGo® Amyloidosis in late 2024, followed by the 2025 launch of EchoGo® Score to enhance HFpEF detection [3]. The company's AI technology is designed to assist hospitals by reducing unnecessary tests, streamlining workflows, and enabling earlier initiation of treatment, aiming to enhance the effectiveness of medical interventions while reducing costs [2].
EchoGo® Heart Failure is the first and only AI platform capable of identifying Heart Failure with Preserved Ejection Fraction (HFpEF) from routine echocardiograms. The recent addition of an AI-powered probability scoring system allows for a nuanced, continuous assessment of HFpEF likelihood, reducing diagnostic uncertainty and aiding clinical decision-making [3].
The platform also supports early detection of cardiac amyloidosis, a condition often underdiagnosed but treatable if caught early. EchoGo® Amyloidosis serves as an automated machine learning-based screening tool specifically indicated for adults aged 65 and older [1][4].
Ultromics has secured substantial funding, including a $55 million Series C round in July 2025. This funding supports nationwide expansion, broader clinical adoption, product pipeline growth, and integration into routine cardiac care workflows without added hardware or complexity [1][2].
The funding round was co-led by L&G, Allegis Capital, and Lightrock, with continued backing from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University [2]. The Series C funding round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases [2].
Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the USA's Midwest, with growing adoption and partnerships across flagship institutions [2]. Medicare reimbursement is now in place for both outpatient and inpatient use of EchoGo®, positioning the company for scaled adoption across U.S. hospitals [1].
According to industry experts, Ultromics' platform addresses a critical blind spot in cardiology by enabling physicians to detect subtle, treatable heart failure cases earlier, potentially saving lives by pairing advanced AI diagnostics with novel treatment advances [1][2]. The company is also actively strengthening collaborations with health systems and clinical leaders to further improve patient outcomes amid the growing heart failure crisis [2].
In conclusion, Ultromics’ AI-driven platform is currently well-positioned as a transformative tool in cardiology, particularly for HFpEF and cardiac amyloidosis detection, with FDA backing, reimbursement support, and expanding clinical adoption driving its impact on improving diagnosis, treatment guidance, and ultimately patient survival [1][3][4].
[1] Ultromics. (2025). Press Release: Ultromics Secures $55 Million Series C Funding to Accelerate AI-Powered Heart Failure Diagnostics. Retrieved from https://www.ultromics.com/news/ultromics-secures-55-million-series-c-funding-to-accelerate-ai-powered-heart-failure-diagnostics
[2] MedCity News. (2025). Ultromics raises $55 million to bring AI-powered diagnostics to heart failure. Retrieved from https://medcitynews.com/2025/07/ultromics-raises-55-million-to-bring-ai-powered-diagnostics-to-heart-failure/
[3] MobiHealthNews. (2025). Ultromics receives FDA clearance for EchoGo Amyloidosis, launches EchoGo Score for HFpEF detection. Retrieved from https://www.mobihealthnews.com/content/ultromics-receives-fda-clearance-echogo-amyloidosis-launches-echogo-score-hfpef-detection
[4] Heart Rhythm Society. (2025). Ultromics' EchoGo® Amyloidosis receives FDA clearance. Retrieved from https://www.hrsonline.org/news/ultromics-echogo-amyloidosis-receives-fda-clearance
- The Ultromics' AI technology, which has received FDA clearance for EchoGo® Amyloidosis, is not only revolutionizing cardiology diagnostics but also aims to make a significant impact on health-and-wellness by early detection of medical-conditions such as cardiac amyloidosis.
- As part of its mission to enhance health-and-wellness and reduce costs associated with cardiovascular diseases, Ultromics' AI-driven platform is designed to streamline business workflows and reduce unnecessary tests in hospitals.
- The success of Ultromics, which is supported by substantial finance from investors like L&G, Allegis Capital, and Lightrock, showcases the potential for technology to improve finance aspects of medical-conditions, like heart failure, by driving wider clinical adoption and integration into routine care.
